H1 Blog

JULY 30, 2024

The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.” Find out more by requesting a demo today.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

H1 Blog

JUNE 7, 2023

Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. Performance data can also lead to more efficient and cost-effective trial designs by allowing research teams to identify areas in which additional resources may be needed to support successful outcomes. The Michael J.

Trials 52

Trials Clinical Trials Pharma Companies Clinical Development 52

H1 Blog

JULY 5, 2023

Improving Diversity Belongs to Everyone For example, if a certain population is not represented at a particular site due to economic or cultural reasons, companies should develop strategies for recruiting participants from that population. To learn more about how H1 can help diversify your HCP engagement strategy, request a demo.

Clinical Trials 52

Clinical Trials Drugs Trials Drug Development 52

H1 Blog

MARCH 27, 2023

MSLs play a critical role at every stage of the product life cycle: from connecting the company with experts who can help identify unmet healthcare needs and evidence gaps that inform research efforts to educating scientific and medical leaders on how a new therapeutic serves patient needs.

Science 52

Science Pharma Companies Pharmaceutical Companies Treatment 52